Blank, S. V., Christos, P., Curtin, J. P., Goldman, N., Runowicz, C. D., Sparano, J. A., . . . Muggia, F. M. (2010). Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment. Gynecologic oncology, 119(3), 451-456. https://doi.org/10.1016/j.ygyno.2010.08.008
Chicago-Zitierstil (17. Ausg.)Blank, Stephanie V., Paul Christos, John P. Curtin, Noah Goldman, Carolyn D. Runowicz, Joseph A. Sparano, Leonard Liebes, Helen X. Chen, und Franco M. Muggia. "Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment." Gynecologic Oncology 119, no. 3 (2010): 451-456. https://doi.org/10.1016/j.ygyno.2010.08.008.
MLA-Zitierstil (9. Ausg.)Blank, Stephanie V., et al. "Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment." Gynecologic Oncology, vol. 119, no. 3, 2010, pp. 451-456, https://doi.org/10.1016/j.ygyno.2010.08.008.